INFUSE BONE GRAFT
Medtronic, Inc. · Decision date Aug 26, 2026
What did the FDA approve?
FDA records P050053/S066 as a supplement to PMA P050053, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 26, 2026.
FDA approval order statement
Approval for a change to the potency testing of rhBMP-2 used in the manufacturing of INFUSE Bone Graft.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Dental
- Decision date
- Aug 26, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P050053/S066
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- NPZ
- Decision code
- APPR
- Decision date
- Aug 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Bone grafting material, dental, with biologic component.
- Applicant
- Medtronic, Inc.
- Product code
- NPZ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P050053/S066 received
Application receipt date recorded by FDA.
P050053/S067 · Related supplement
INFUSE Bone Graft
P050053/S068 · Related supplement
INFUSE Bone Graft
P050053/S069 · Related supplement
Infuse Bone Graft
P050053/S066 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P050053. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050053
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
INFUSE Bone GraftP050053/S067 | Medtronic, Inc. | PMA supplement | Feb 24, 2026 | FDA |
INFUSE Bone GraftP050053/S068 | Medtronic, Inc. | PMA supplement | Mar 19, 2026 | FDA |
Infuse Bone GraftP050053/S069 | Medtronic, Inc. | PMA supplement | Jul 28, 2026 | FDA |
Explore the linked device profile
Other records with product code NPZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Lynch Biologics, LLC | PMA supplement | Aug 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 1800 Pyramid Pl., Memphis, TN, 38132
Sources and methodology
- Original FDA record: P050053/S066
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


